The Doctor is in.
Diabetes Questions ?
Risk Factor Management can prevent Heart Attacks and Strokes
Video - Diabetes Office Visit trainer
PURCHASE IPHONE/IPAD APP
Sunday, December 23, 2012
Metformin ( glucophage )reduces Cardiovascular risk
The December 10,2012 issue of Diabetes Care has an article of interest related to yesterdays discussion of glipizide and metformin.
ffects of Metformin Versus Glipizide on Cardiovascular Outcomes in Patients With Type 2 Diabetes and Coronary Artery Disease.
They studied 304 patients with Type 2 Diabetes with a history of coronary artery disease.
Patients were randomly assigned to either metformin 1.5 gms/day or glipizide 30 mg/day.
The medium followup was 5 years and both groups achieved similar A1c results
( 7.1 in the glipizide group and 7.0 in the meformin group )
Treatment with metformin for 3 years substantially reduced major cardiovascular events during the 5 year followup.
Have Fun, Be Smart and read pages 44 and 45 in
Diabetes Office Visit
talk to your doctor about metformin
David Calder, MD
Share to Twitter
Share to Facebook
Share to Pinterest
Post a Comment
Your comments and questions are appreciated. David Calder,MD
Post Comments (Atom)